Erectile Dysfunction - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Erectile Dysfunction - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2015', provides an overview of the Erectile Dysfunction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Erectile Dysfunction Overview 9
Therapeutics Development 10
Pipeline Products for Erectile Dysfunction - Overview 10
Pipeline Products for Erectile Dysfunction - Comparative Analysis 11
Erectile Dysfunction - Therapeutics under Development by Companies 12
Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes 14
Erectile Dysfunction - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Erectile Dysfunction - Products under Development by Companies 19
Erectile Dysfunction - Products under Investigation by Universities/Institutes 21
Erectile Dysfunction - Companies Involved in Therapeutics Development 22
Acorda Therapeutics, Inc. 22
Apricus Biosciences, Inc. 23
Aprogen, Inc. 24
Bioheart, Inc. 25
Biolab Sanus Farmaceutica Ltda. 26
Corridor Pharmaceuticals Inc. 27
Furiex Pharmaceuticals, Inc. 28
Futura Medical plc 29
Hanmi Pharmaceuticals, Co. Ltd. 30
IntelGenx Corp. 31
Mezzion Pharma Co. Ltd. 32
Mitsubishi Tanabe Pharma Corporation 33
NAL Pharmaceuticals Ltd. 34
Pacific Therapeutics Ltd. 35
Palatin Technologies, Inc. 36
Pharmicell Co., Ltd. 37
Sagene Pharmaceuticals, Inc. 38
Suda Ltd 39
Yungjin Pharm Ind. Co., Ltd. 40
Erectile Dysfunction - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
AdipoCell - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
alprostadil - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AP-102 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BL-214 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
cimaglermin alfa - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dapoxetine hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HCP-1302 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HCP-1303 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Immpocellgram - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MED-2002 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Next Generation Melanocortin Receptor IV Agonist - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PL-6983 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
selegiline + PDE-5 Inhibitor - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
sildenafil citrate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
sildenafil citrate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
sildenafil citrate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
T-6932 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tadalafil - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
tadalafil - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TPN-729 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
udenafil - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
YBH-1603 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Erectile Dysfunction - Recent Pipeline Updates 83
Erectile Dysfunction - Dormant Projects 94
Erectile Dysfunction - Discontinued Products 97
Erectile Dysfunction - Product Development Milestones 98
Featured News & Press Releases 98
Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 98
Aug 28, 2012: Acorda Announces GGF2 Preclinical Data On Treatment Of Erectile Dysfunction 98
Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India 99
Sep 08, 2011: Sagene Completes Pre-IND Meeting With FDA For Dual-Action Erectile Dysfunction Drug 99
Oct 12, 2010: Dong-A Launches Zydena For Daily Treatment Of Erectile Dysfunction In Korea 100
Sep 02, 2010: IntelGenx Achieves Positive Bioequivalence Results For Erectile Dysfunction Film Product 100
Nov 19, 2009: Once-A-Day Dosing Clinical Study Of Udenafil For Erectile Dysfunction Completed By Dong-A Pharmaceutical Co., Ltd. 100
Nov 11, 2009: ZYDENA Poised To Enter Global Market With Phase III Clinical Trial Starting For US FDA Approval 101
Sep 11, 2009: New Drug Udenafil By Dong-A PharmTech Co. Ltd For Erectile Dysfunction in US Trials 102
Aug 28, 2009: Dong-A Receives Approval For Zydena For Treatment Of Erectile Dysfunction 102
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Tables
Number of Products under Development for Erectile Dysfunction, H1 2015 10
Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Erectile Dysfunction - Pipeline by Acorda Therapeutics, Inc., H1 2015 22
Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H1 2015 23
Erectile Dysfunction - Pipeline by Aprogen, Inc., H1 2015 24
Erectile Dysfunction - Pipeline by Bioheart, Inc., H1 2015 25
Erectile Dysfunction - Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 26
Erectile Dysfunction - Pipeline by Corridor Pharmaceuticals Inc., H1 2015 27
Erectile Dysfunction - Pipeline by Furiex Pharmaceuticals, Inc., H1 2015 28
Erectile Dysfunction - Pipeline by Futura Medical plc, H1 2015 29
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 30
Erectile Dysfunction - Pipeline by IntelGenx Corp., H1 2015 31
Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 32
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 33
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 34
Erectile Dysfunction - Pipeline by Pacific Therapeutics Ltd., H1 2015 35
Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H1 2015 36
Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H1 2015 37
Erectile Dysfunction - Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 38
Erectile Dysfunction - Pipeline by Suda Ltd, H1 2015 39
Erectile Dysfunction - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 40
Assessment by Monotherapy Products, H1 2015 41
Assessment by Combination Products, H1 2015 42
Number of Products by Stage and Target, H1 2015 44
Number of Products by Stage and Mechanism of Action, H1 2015 46
Number of Products by Stage and Route of Administration, H1 2015 48
Number of Products by Stage and Molecule Type, H1 2015 50
Erectile Dysfunction Therapeutics - Recent Pipeline Updates, H1 2015 83
Erectile Dysfunction - Dormant Projects, H1 2015 94
Erectile Dysfunction - Dormant Projects (Contd..1), H1 2015 95
Erectile Dysfunction - Dormant Projects (Contd..2), H1 2015 96
Erectile Dysfunction - Discontinued Products, H1 2015 97